Preoperative SGLT2 Inhibitor Users Have Increased Risk for Postoperative Euglycemic Ketoacidosis
By Elana Gotkine HealthDay Reporter
TUESDAY, May 13, 2025 -- Patients using sodium-glucose cotransporter 2 inhibitors (SGLT2i) preoperatively have a slightly increased risk for postoperative euglycemic ketoacidosis (eKA) but a lower risk for acute kidney injury (AKI) and mortality, according to a study published online April 30 in JAMA Surgery.
Roberta Teixeira Tallarico, M.D., from the University of California, San Francisco, and colleagues examined the risk for postoperative eKA, AKI, and mortality within 30 days after surgery among preoperative long-term SGLT2i users versus nonusers in a multicenter, propensity-matched retrospective case-control study. Adults using SGLT2i preoperatively who underwent inpatient surgical procedures were compared to a propensity score-matched control group in a 1:5 ratio (7,439 users and 33,489 nonusers).
The researchers found that SGLT2i use was associated with an increased risk for eKA (odds ratio, 1.11), but with reduced risks for perioperative AKI and 30-day mortality (odds ratios, 0.69 and 0.70, respectively). Thirty days after surgery, the mortality rate was 1.1 and 1.6 percent among SGLT2i users and nonusers, respectively. The median hospital length of stay increased by three days for those presenting with eKA (median: six versus three days for those with and without eKA).
"The consequences of developing perioperative eKA are not fully understood; however, perioperative eKA may necessitate escalated interventions (i.e., insulin administration or continuous dextrose infusion), which could be associated with an increased risk of prolonged hospitalization or unplanned admission to an intensive care unit," the authors write.
One author disclosed ties to the pharmaceutical and health care industries.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted May 2025
Read this next
U.S. Children Became Increasingly Unhealthy in Recent Decades
WEDNESDAY, July 16, 2025 -- The health of U.S. children worsened across a wide range of health indicator domains during the past 17 years, according to a study published online...
ENDO: Superior Weight Loss Seen With Tirzepatide and Menopausal Hormone Therapy Use
TUESDAY, July 15, 2025 -- In postmenopausal women with overweight or obesity receiving tirzepatide, use of menopausal hormone therapy (MHT) is associated with superior weight loss...
Velar Adhesion Reduces Cleft Width Prior to Palatoplasty in Cleft Lip
TUESDAY, July 15, 2025 -- For patients with unilateral cleft lip and palate (UCLP), velar adhesion (VA) reduces cleft width prior to palatoplasty and is associated with a lower...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.